Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
Open Access
- 1 May 2012
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (11) , 1826-1832
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 33 references indexed in Scilit:
- Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in MiceMolecular Cancer Therapeutics, 2011
- Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumoursBritish Journal of Cancer, 2011
- MicroRNA dysregulation in colorectal cancer: a clinical perspectiveBritish Journal of Cancer, 2011
- A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumorsBMC Medical Genomics, 2010
- MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancerBMC Cancer, 2010
- MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancerBritish Journal of Cancer, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Altered Expression of miR-21, miR-31, miR-143 and miR-145 Is Related to Clinicopathologic Features of Colorectal CancerOncology, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006